Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV001212675 | SCV001384267 | uncertain significance | Pancreatic adenocarcinoma | 2022-09-07 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 202 of the PALLD protein (p.Arg202His). This variant is present in population databases (rs758090588, gnomAD 0.004%). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C25"). ClinVar contains an entry for this variant (Variation ID: 942652). This variant has not been reported in the literature in individuals affected with PALLD-related conditions. |
| Ambry Genetics | RCV004033862 | SCV002725638 | uncertain significance | not specified | 2024-02-22 | criteria provided, single submitter | clinical testing | The p.R689H variant (also known as c.2066G>A), located in coding exon 10 of the PALLD gene, results from a G to A substitution at nucleotide position 2066. The arginine at codon 689 is replaced by histidine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |